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Abstract
Introduction: Chronic kidney disease (CKD) is a significant public health problem and it is not possible to precisely predict its progression to termi-
nal renal failure. According to current guidelines, CKD stages are classified based on the estimated glomerular filtration rate (eGFR) and albuminuria. 
Aims of this study were to determine the reliability of predictive equation in estimation of CKD prevalence in Croatian areas with endemic nephro-
pathy (EN), compare the results with non-endemic areas, and to determine if the prevalence of CKD stages 3-5 was increased in subjects with EN. 
Materials and methods: A total of 1573 inhabitants of the Croatian Posavina rural area from 6 endemic and 3 non-endemic villages were enrolled. 
Participants were classified according to the modified criteria of the World Health Organization for EN. Estimated GFR was calculated using Chronic 
Kidney Disease Epidemiology Collaboration equation (CKD-EPI). 
Results: The results showed a very high CKD prevalence in the Croatian rural area (19%). CKD prevalence was significantly higher in EN then in non 
EN villages with the lowest eGFR value in diseased subgroup. 
Conclusions: eGFR correlated significantly with the diagnosis of EN. Kidney function assessment using CKD-EPI predictive equation proved to be a 
good marker in differentiating the study subgroups, remained as one of the diagnostic criteria for EN. 
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Over the past three decades the prevalence of 
chronic kidney disease (CKD) is on the rise world-
wide (1). The Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) consequently published guidelines 
for diagnosis of CKD and postulated the five stag-
es for disease classification (CKD1-5), based on dis-
ease severity. Glomerular filtration rate (GFR) was 
set as the most important criteria for disease se-
verity determination according to the 2002 guide-
lines (2).
In order to better assess disease progression, in 
2012 the Kidney Disease: Improving Global Out-
comes (KDIGO) group revised the CKD staging sys-
tem and issued the new KDIGO CKD guidelines (3). 
This new disease staging system was based on five 
eGFR stages (the third stage (G3) was furthermore 
stratified into substages G3a and G3b) and three 
stages of albuminuria determined on the basis of 
the albumin-to-creatinine ratio (ACR). However 
the definition of CKD did not change, i.e. CKD was 
defined as an eGFR < 60 mL/min/1.73m2 during 
the period of 3 months (4). Based on these indica-
tors and following the results of a meta-analysis 
that confirmed the independent value of estimat-
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ed GFR (eGFR) and albuminuria for predicting 
mortality due to cardiovascular events, acute kid-
ney injury, progressive CKD and end-stage renal 
disease (ESRD), a “heat map” was generated ac-
cording to which patients could be classified into 
four risk categories (depending on renal and car-
diovascular outcomes): low (stages G1-A1, G2-A1), 
moderate (stages G1-A2, G2-A2, G3a-A1), high (G1-
A3, G2-A3, G3a-A2, G3b-A1) and very high risk 
(G3a-A3, G3b-A2-3, all G4 and G5) (5).
Epidemiological data on the prevalence of CKD in 
Croatia are still missing despite the increasing 
awareness of public health problems associated 
with CKD. There is only one preliminary report on 
prevalence of CKD in Croatian rural population 
which showed that CKD is more frequently pre-
sent in this area comparing to other regions (6). 
One specific cause of CKD in Croatia is endemic 
nephropathy (EN). It was reported in Posavina and 
comprises 14 villages situated west of the city of 
Slavonski Brod (Figure 1) with a population of 
12,686 inhabitants according to the census from 
2011 (7).
EN is a chronic tubulointerstitial nephropathy with 
subtle onset and characteristically gradual pro-
gression to ESRD with no significant gender differ-
ence  - some reports in which EN is more frequent 
in women than in men are probably incorrect be-
cause before developing a kidney disease many 
men die of some cardiovascular disease (8).
The cause of EN is chronic aristolochic acid poison-
ing through contaminated food in genetically pre-
disposed individuals (9). The adducts of aristoloch-
ic acid were isolated from the renal cortex of EN pa-
tients only, and not from patients with CKD of dif-
ferent etiology. Furthermore, a fingerprint muta-
tion of the p53 gene (an AT:TA transversion) was 
confirmed in EN patients (9). Today, EN is consid-
ered as an environmental form of aristolochic acid 
nephropathy. Clinical course and disease progres-
sion of EN do not differ from other tubulointersti-
tial nephropathies (10). For now, there are no spe-
cific biomarkers for EN diagnosis and diagnostic 
criteria have not been precisely established. This 
means that various countries used different criteria. 
However, all these criteria have serious disadvan-
tages (outdated, uneven and not in accordance 
with the new recommendations for the classifica-
tion of renal diseases). Recently, a consensus docu-
ment with new diagnostic criteria was accepted 
and it is hoped that researcher from all countries 
will start to use these compilation of criteria (11).
Figure 1. Endemic focus in Croatia with respective epidemiological data. The average prevalence of endemic nephropathy in en-
demic villages from 1980 to 1991 is presented as percentage (20). EN-villages enrolled in this study are rounded with a full black line; 
other EN villages (not included in this study ) are rounded with dashed black line; non-EN villages are rounded with a dotted line.
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In EN, GFR is, just as in other CKD, considered a 
marker of overall renal function (12). Furthermore, 
individual patients’ risk estimation, prognosis of 
the disease clinical course and treatment decisions 
are based upon patients’ GFR. At the population 
level, it is important to accurately determine the 
prevalence of CKD to enable patient care planning 
and to estimate the need for renal replacement 
therapy as this is essential for planning public 
health budget, especially in areas with high inci-
dence of CKD such as the Croatian areas with EN.
Because of higher exposure to aristolochic acid in 
the past, prevalence of CKD is higher in Croatian 
endemic area than in non-endemic villages. Our 
aims were to determine the prevalence of CKD us-
ing Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) equation and to analyse diagnos-
tic value of eGFR in diagnosis and stratification of 
subjects from EN area. The results obtained con-
tribute to the detection of differences in the prev-
alence of CKD stages and in their frequency in en-
demic and non-endemic villages.
Materials and methods
Subjects
This cross-sectional observational study is based 
on data collected by field research between 2008 
and 2010 as a part of the Croatian Ministry of Sci-
ence research project entitled “Endemic Nephrop-
athy in Croatia: Epidemiology, Diagnosis, Etiology” 
(108-0000000329). The survey was approved by 
the Ethical Committee of the Croatian National In-
stitute of Public Health, the School of Medicine 
University of Zagreb and General Hospital ‘Dr. Jo-
sip Benčević’ Slavonski Brod. 
A total of 1573 adult inhabitants from six endemic 
villages (Pričac, Slavonski Kobaš, Živike, Šumeće, 
Zbjeg and Dobočac) and three non-endemic vil-
lages (Klakar, Donja Bebrina, Rastušje) were invited 
to participate on a door-to-door basis and were 
enrolled after signing informed consent. The study 
included significant and comparable percentages 
of participants from each village over previous re-
searches (Table 1) (13). A physician, nurse and tech-
nician went to the village where an extensive epi-
demiological questionnaire was completed and 
clinical examination (including measurement of 
blood pressure, height, weight) and sampling for 
laboratory analyses of blood and urine were per-
formed. Venous blood (4 mL in K2EDTA blood col-
lection tube for red blood cell count and 8.5 mL in 
tube with Silica Clot Activator-SST for biochemis-
try tests; all BD Diagnostic, Sparks, USA) and 50 mL 
of second morning urine sample (Sterile Specimen 
Collection Cup of 120 mL without preservative; BD 
Diagnostic, Sparks, USA) were collected from each 
subject. Blood samples were centrifuged 10 min-
utes at 3500 rpm within 2 hours of collection. All 
samples were transported the same day (in condi-
tions that ensure the stability of the analyte) to the 
Department of Laboratory Diagnostics, University 
Hospital Center Zagreb, and testing was per-
formed immediately upon acceptance.
According to the modified World Health Organiza-
tion (WHO) criteria, which have been used in Croa-
tia for the last 40 years, participants in endemic vil-
lages were classified into diseased, suspected of 
having EN, those at risk of developing EN and oth-
ers, farmers from villages who were completely 
unrelated to EN (14). Subjects from endemic villag-
es with missing key data for classification were not 
included in the study. Inclusion criteria were based 
on the following data: (a) positive family history of 
EN and/or living > 20 years in EN village; (b) low 
molecular weight proteinuria (alpha1-microglobu-
Village Adult population, N
Enrolled 
population, N (%)
Pričac 76 51 (67)
SLavonski Kobaš 893 585 (66)
Živike 183 103 (56)
Šumeće 415 252 (61)
Zbjeg 336 129 (38)
Dubočac 163 106 (65)
Klakar 201 90 (45)
Donja Bebrina 317 153 (48)
Rastušje 219 104 (47)
Total 2803 1573 (56)
Table 1. The percentage of the population enrolled in the study
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lin > 10 mg/L or alpha1-microglobulin/creatinine > 
14 mg/g); (c) serum creatinine > 132.6 µmol/L; (d) 
anaemia (haemoglobin (Hb) < 120 g/L if male, Hb 
< 113 g/L if female), and (e) exclusion of other renal 
diseases (including diabetes). 
Participants were considered “diseased” if they 
were positive for criteria listed as (a), (b), (c), (d) and 
(e); or (b), (c), (d) and (e); and/or (a), (b), (d) and (e). 
Patients with positive criteria listed as (a) and (b) or 
(b) and (d) were “suspected of having EN” and “at 
risk” if they were from a family with EN. To exclude 
other renal diseases, laboratory data and imagin-
ing techniques were used when necessary. The 
control group was comprised of subjects who did 
not have EN according to the previously listed cri-
teria (subjects from non-endemic villages).
Due to the fact that diabetes and hypertension are 
major causes of CKD, participants were additional-
ly divided into subjects with hypertension accord-
ing to the European Society of Hypertension clas-
sification (i.e. systolic blood pressure of ≥ 140 
mmHg and diastolic blood pressure of ≥ 90 
mmHg, measured with an automated device (Om-
ron HEM-907, Matsusaka, Japan); and/or taking any 
antihypertensive agent) and subjects with diabe-
tes (DM) according to the American Diabetes As-
sociation guidelines (fasting blood glucose ≥ 7.0 
mmol/L measured by enzymatic UV method with 
hexokinase and/or taking drugs to lower blood 
glucose) (15,16). Furthermore, participants were di-
vided into three age groups: group I (age 18 - 42); 
group II (age 43 - 66), and group III (age ≥ 67).
Methods
Blood and urine samples were analyzed using 
standard laboratory methods. Red blood cell 
count (RBC) was determined using laser light scat-
tering technology on the Cell Dyn Sapphire (Ab-
bott Diagnostic, Illinois, USA) and Sysmex XE 5000 
(Sysmex Europe GmbH, Norderstedt, Germany) 
analyzers. Serum (SCr) and urine creatinine (UCr) 
were measured on the Olympus AU 2700 analyzer 
(Beckman Coulter, California, USA) using the Jaffé 
kinetic uncompensated method with continuous 
measurement. Calibration was performed using 
proprietary calibrators traceable to isotope dilu-
tion mass spectrometry (IDMS) method and Stand-
ard Reference Material (SRM) 909B of the National 
Institute of Standards and Technology (NIST, USA) 
for serum and the NIST reference material SRM 
914a (substance creatinine purity of 99.7 ± 0.3%) 
for urine samples. Urine alpha1-microglobulin (al-
pha1-MG) was measured by immunonephelomet-
ric assay (on the BN II nephelometer, Siemens 
Healthcare Diagnostics Inc, Tarrytown, USA). Con-
tinuous internal quality control was performed 
throughout the study using quality control materi-
als provided by the respective manufacturers. For 
CKD staging, urine albumin (U-Alb) was measured 
in the second morning sample by immunoneph-
elometric assay (BN II nephelometer, Siemens 
Healthcare Diagnostics Inc, Tarrytown, USA) stand-
ardized using primary ERM-DA470 calibrators with 
a method sensitivity of 3.0 mg/L. The same tests 
were performed in the endemic and the control 
group.
Glomerular filtration rate (eGFR in mL/min/1.73m2) 
was calculated by applying SCr to CKD-EPI equa-
tion (17). The equations are presented below (Eq. 1 
for women and Eq. 2 for men). 
(Eq. 1)
if SCr ≤ 62 μmol/L 
GFR(mL/min/1.73m2) = 144 x (SCr 
(μmol/L) / 62) - 0.329 x (0.993)age (years)
if SCr > 62 μmol/L 
GFR(mL/min/1.73m2) = 144 x (SCr 
(μmol/L) / 62) - 1.209 x (0.993)age (years)
(Eq. 2)
if SCr ≤ 80 μmol/L 
GFR (mL/min/1.73m2) = 141 x (SCr 
(μmol/L)/80) - 0.411 x (0.993)age (years)
if SCr > 80 μmol/L 
GFR (mL/min/1.73m2) = 141 x (SCr 
(μmol/L) / 80) – 1.209 x (0.993)age (years)
Because the CKD-EPI equation was evaluated ac-
cording to the SCr values measured by compen-
sated Jaffé method, SCr values of all subjects were 
corrected before inclusion in the equation using 
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the linear regression equation: y = 0.95 x + 0.44 (y 
= compensated Jaffè; x = uncompensated Jaffè) 
(18).
The revised KDIGO classification was used to de-
fine CKD stages which includes five stages of eGFR: 
G1 (≥ 90 mL/min/1.73m2), G2 (60 - 89 mL/
min/1.73m2), G3a (45 - 59 mL/min/1.73m2), G3b (30 
- 44 mL/min/1.73m2), G4 (15 - 29 mL/min/1.73m2), 
G5 (< 15 mL/min/1.73m2) and three levels of albu-
minuria based on the albumin-to-creatinine ratio 
(ACR): A1 (< 30 mg/g), A2 (30 – 300 mg/g) and A3 
(> 300 mg/g).
CKD prevalence was assessed using the eGFR cal-
culated with CKD-EPI equation. We evaluated the 
overall prevalence of CKD and the prevalence of 
stages 3-5 (CKD3-5) in all subgroups depending on 
gender, age and place of recruitment. CKD was de-
fined as eGFR < 60mL/min/1.73m2.
Statistical analysis
The SPSS software (SPSS Version 18, SPSS Inc., Chi-
cago, USA) was used for statistical analyses, and P-
value below 0.05 was considered statistically sig-
nificant. Normality of data distribution was tested 
with Shapiro-Wilks test. Student t-test, analysis of 
variance and χ2 post hoc test were performed to 
test the differences between groups. In case of 
normal distribution Mann-Whitney test was used. 
The correlation between eGFR and age subgroups 
was analyzed using Pearson correlation. Differenc-
es between three or more groups were analyzed 
in the case of normally distributed variables with 
ANOVA analysis of variance and Tukey-Kramer post 
hoc test. 
Results
A total of 1573 participants were enrolled, 1229 
from EN villages and 344 from non-EN villages. In 
the group of endemic villages, 33 farmers were 
classified as having EN (2.7%), 86 as suspect of hav-
ing EN (6.9%), 268 as those at risk (22%) and 842 
were completely unrelated to EN – so called “oth-
ers” (68%). We failed to find difference in gender 
prevalence within EN- and control villages. The av-
erage age of all participants was 52 years (range 18 
- 90), with statistically significant difference in age 
between males and females in EN villages. In terms 
of body weight and SCr, there were statistically 
significant differences between males and females 
regardless of their place of recruitment, but also 
within EN- and control villages. No statistically sig-
nificant differences regarding diabetes and hyper-
tension were found between subjects from EN 
and control villages (Table 2). Prevalence of CKD in 
the Croatian rural area using CKD-EPI equation 
was very high (19%). Also, CKD prevalence was 
higher in females than in males (21% vs. 18%, P < 
0.001) and significantly higher in EN then in non-
EN villages in both sexes (P < 0.001) (Table 3). No 













(N = 209) 
Males 
(N = 135)










(18 - 85) 0.420
Weight (kg) 78 ± 17 74 ± 16 85 ± 16 < 0.001 80 ± 16 76 ± 16 85 ± 14 < 0.001
Creatinine, serum (µmol/L) 93 ± 59 88 ± 60 102 ± 55 < 0.001 86 ± 51 79 ± 64 93 ± 12 < 0.001
Diabetes mellitus (%) 8.7 9.7 7.0 0.111 9.0 8.6 9.6 0.748
Hypertension (%) 37.0 37.0 37.0 0.935 38.0 37.0 40.0 0.635
EN - endemic nephropathy. Age is presented as median and range (min-max). Weight and creatinine concentrations are presented 
as mean ± standard deviation. Diabetes mellitus and hypertension subgroups were presented as proportions (%). P < 0.05 was 
considered statistically significant.
Table 2. Basic participant characteristics in EN and non-EN villages
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CKD in hypertension and diabetes subgroups of 
participants between EN and non-EN villages (P = 
0.704 and P = 0.945, respectively). The prevalence 
of CKD rose with patient’s age regardless of used 
equation. In EN diseased, CKD prevalence was the 
highest (88%). 
There was no statistically significant difference of 
eGFR between age groups in EN and non-EN vil-
lages. Compared according to gender, significantly 
higher eGFR were observed in males than females. 
This difference was more pronounced in subjects 
from EN villages (Table 4). The lowest eGFR value 
was expected in diseased (eGFR in all subgroups 
are presented in Table 5). There was no statistically 
significant difference between subjects with or 
without diabetes in eGFR. Between subjects with 
or without hypertension, no statistically significant 
difference was found in eGFR, with lower values in 
hypertensive subjects. 
Discussion
Diagnosis and staging of CKD depends on the cor-
rect calculation of GFR. We tested differences in 
eGFR among subjects from EN and non-EN areas 
Table 3. CKD prevalence and distribution of CKD stages in EN and non-EN villages
eGRF stage (%) CKD prevalence 
(%)G1 G2 G3a G3b G4 G5 
EN-villages  (N = 1229) 35.0 51.0 7.7 4.1 1.5 0.8 14
non EN-villages (N = 344) 41.0 53.0 4.7 0.6 0.0 0.3 5.5
Data are shown as percentages for each eGFR stage. CKD prevalence was assessed using the eGFR calculated with CKD-EPI 
equation. eGFR - estimated glomerular filtration rate. CKD - chronic kidney disease. EN - endemic nephropathy. 






















(83 - 89) < 0.001
Data are shown as mean (95% confidence interval). P < 0.05 is considered statisticall significant. eGFR - estimated glomerular 
filtration rate. EN - endemic nephropathy.
Subgroup eGFR (mL/min/1.73m2)
diseased (N = 33) 32 ± 27
suspected (N = 86) 64 ± 22
at risk (N = 268) 86 ± 17
others (N = 842) 83 ± 19
non-EN subjects (N = 344) 85 ± 17
Data shown as mean ± standard deviation. eGFR - estimated 
glomerular filtration rate. EN - endemic nephropathy.
Table 5. eGFR in EN and control subgroups according to the 
CKD-EPI equation
by applying serum creatinine values to recom-
mended CKD-EPI predictive equation. 
CKD-EPI equation differentiated healthy from dis-
eased subjects well. Participants from EN villages 
had higher prevalence of CKD than participants 
from non-EN villages. There are no new cases of 
EN today, and participants who were classified into 
diseased subgroup thirty years ago, today have 
more CKD3-5 stages than others in EN villages. No 
statistically significant difference was observed in 
the eGFR between patients with or without diabe-
tes, although CKD-EPI equation underestimated 
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their GFR (rather consistently with literature data) 
(19). In the hypertension group, significantly more 
G3a, G3b, G4 and G5 CKD stages were observed 
(20% vs. 7.7% in the non hypertension group). High 
prevalence of CKD3-5 stages in that subgroup 
could be a result of subjects lifestyle – high preva-
lence of obesity and hypertension, poor control of 
salt intake and untreated hypertension. 
We are aware that this study has several limita-
tions: recommended methods for serum creati-
nine measurements were not used in the study 
(enzymatic method has been applied in the De-
partment of Laboratory Diagnostics, University 
Hospital Center Zagreb since 2014 and study is 
based on data collected between 2008 and 2010) 
and creatinine was determined only once so we 
do not know if there was a clinically significant dif-
ference in re-determining (based on the analytical 
and biological variation of serum creatinine the 
clinically significant difference for eGFR is about 
14%). Also, eGFR in our study group, were not 
compared with the GFR measured using the gold 
standard  with an ideal filtration marker. 
However, the value of our study is that we found 
differences in the CKD prevalence and the fre-
quency of certain stages of CKD in EN and non-EN 
villages. The prevalence of EN diseased (2.7%) and 
suspected (6.9%) patients is in accordance with 
the previously described incidence decline trend. 
This percentage of diseased and suspected pa-
tients explain the difference in CKD prevalence 
and it is an important indicator that in the coming 
years, regardless of if there will be new cases of EN, 
the number of new patients to start with renal re-
placement therapy will be higher in EN villages 
than in control. These results confirm that the as-
sessment of kidney function with predictive equa-
tions proved to be a good marker in differentiating 
the study subgroups in the EN areas and it should 
therefore remain the diagnostic criteria for EN, and 
that the optimal equation for GFR estimation is 
CKD-EPI equation.
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